DRIO vs. SRTS, ECOR, FONR, LNSR, GUTS, MLSS, MGRM, EDAP, HYPR, and STIM
Should you be buying DarioHealth stock or one of its competitors? The main competitors of DarioHealth include Sensus Healthcare (SRTS), electroCore (ECOR), FONAR (FONR), LENSAR (LNSR), Fractyl Health (GUTS), Milestone Scientific (MLSS), Monogram Orthopaedics (MGRM), Edap Tms (EDAP), Hyperfine (HYPR), and Neuronetics (STIM). These companies are all part of the "medical equipment" industry.
DarioHealth vs.
DarioHealth (NASDAQ:DRIO) and Sensus Healthcare (NASDAQ:SRTS) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, community ranking, institutional ownership, dividends, analyst recommendations, risk and earnings.
Sensus Healthcare has higher revenue and earnings than DarioHealth. DarioHealth is trading at a lower price-to-earnings ratio than Sensus Healthcare, indicating that it is currently the more affordable of the two stocks.
DarioHealth presently has a consensus target price of $4.00, indicating a potential upside of 476.37%. Sensus Healthcare has a consensus target price of $12.50, indicating a potential upside of 90.55%. Given DarioHealth's higher probable upside, equities research analysts clearly believe DarioHealth is more favorable than Sensus Healthcare.
DarioHealth has a beta of 1.39, suggesting that its share price is 39% more volatile than the S&P 500. Comparatively, Sensus Healthcare has a beta of 1.21, suggesting that its share price is 21% more volatile than the S&P 500.
In the previous week, DarioHealth had 3 more articles in the media than Sensus Healthcare. MarketBeat recorded 4 mentions for DarioHealth and 1 mentions for Sensus Healthcare. Sensus Healthcare's average media sentiment score of 0.49 beat DarioHealth's score of 0.29 indicating that Sensus Healthcare is being referred to more favorably in the news media.
33.4% of DarioHealth shares are held by institutional investors. Comparatively, 25.3% of Sensus Healthcare shares are held by institutional investors. 16.5% of DarioHealth shares are held by insiders. Comparatively, 9.4% of Sensus Healthcare shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
DarioHealth received 56 more outperform votes than Sensus Healthcare when rated by MarketBeat users. However, 68.42% of users gave Sensus Healthcare an outperform vote while only 67.04% of users gave DarioHealth an outperform vote.
Sensus Healthcare has a net margin of 22.54% compared to DarioHealth's net margin of -205.62%. Sensus Healthcare's return on equity of 17.99% beat DarioHealth's return on equity.
Summary
Sensus Healthcare beats DarioHealth on 13 of the 19 factors compared between the two stocks.
Get DarioHealth News Delivered to You Automatically
Sign up to receive the latest news and ratings for DRIO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
DarioHealth Competitors List
Related Companies and Tools
This page (NASDAQ:DRIO) was last updated on 1/20/2025 by MarketBeat.com Staff
Free DRIO Stock Alerts